Fviii point-of-care monitoring device and APP

Active Project Grant Awarded Last action

Award ID
R44HL151147
Recipient
Awarding agency
Obligated
$6,197,958

Award facts

Assistance listing
93.837 Cardiovascular Diseases Research
Completion date 95% complete
Originally
Funding
  • $5,473,281.00 Federal
  • $724,677.00 Non-federal
Place of performance
Bedford, MA 01730, USA

Award details come from USAspending.gov.

Transactions

Action Federal Non-federal Date
Amendment $50,000 $0
Amendment Taba supplement for hemophilia point-of-care device $1,000,000 $0
Amendment $1,000,000 $0
Amendment Hemophilia point-of-care monitoring device and APP $500,000 $0
Amendment $0 $0
Amendment $0 $0
Amendment $724,677 $0
Amendment $724,677 $0
Amendment $724,677 $724,677
Amendment $0 $0
Amendment $0 $0
Amendment Fviii point-of-care monitoring device and APP summary/abstract hemophilia a results from a deficiency of fviii-activity and can result in severe bleeding.… $0 $0
Original award $749,250 $0
Show all 13

Quick answers

Who received award R44HL151147?

R44HL151147 was awarded to The DNA Medicine Institute, Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on September 10, 2020.

How much is award R44HL151147 worth?

$6,197,958 has been obligated on R44HL151147: $5,473,281 in federal funding and $724,677 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award